TY - JOUR AU - Okascharoen, Chusak PY - 2020/10/01 Y2 - 2024/03/29 TI - Editor's Note JF - Ramathibodi Medical Journal JA - Rama Med J VL - 43 IS - 3 SE - Editor's Note DO - UR - https://he02.tci-thaijo.org/index.php/ramajournal/article/view/246252 SP - AB - <p style="text-align: justify;">As the end of third quarter of 2020, the coronavirus disease 2019 (COVID-19) situation is still worsening in many countries especially overcrowded country like India. Controlling of infection in overcrowded communities are quite challenging. Several clinical trials of vaccine of COVID-19 are ongoing with few candidates have already go to phase 3 trial. It needs to be noted that the first COVID-19 vaccine has been registered in Russia since August.<sup>1</sup> The data of safety and efficacy of this COVID-19 vaccine came from only 38 subjects.<sup>2</sup> This fact makes scientists around the world expressed some doubt of the data.<sup>3</sup> However, the lead author of the report denied all the suspicions.</p><p style="text-align: justify;">In term of scientific publication of COVID-19, recent searching in PubMed reveal over 58 000 results and 3489 clinical trials registered in ClinicalTrials.gov. This is a huge number for the period of less than 10 months. We all realize that COVID-19 has change the world in many aspects, and scientific publication is one of those.</p><p>&nbsp;</p> ER -